Compare Inovio Pharmaceuticals Inc (INO) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Direxion Daily TSLA Bull 2X Shares trades at $10.42 (market cap $3.97B). The key difference: Direxion Daily TSLA Bull 2X Shares is far larger — about 35.4× Inovio Pharmaceuticals Inc's market cap, and Direxion Daily TSLA Bull 2X Shares is more actively traded (38,458,237 versus 3,201,278). Which is the better fit depends on your goals.
| INO | TSLL | |
|---|---|---|
Market Cap | $112.19M | $3.97B |
Volume | 3,201,278 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.65 | $23.03 |
52-Week Low | $0.66 | $6.74 |
Typical Hold Time | 43 Days | — |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.56, up 4.04% today, with a neutral technical signal overall despite bullish moving averages. The leveraged ETF amplifies Tesla's daily returns, with recent momentum driven by Tesla's Cybercab event anticipation. Key support sits at $10 with resistance at $11, while RSI indicators show mixed signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF tracking Tesla, TSLL offers amplified exposure but carries significant volatility risks from daily rebalancing effects. The fund's performance remains entirely dependent on Tesla's stock movements, with recent news highlighting both opportunity from Tesla events and the structural risks of holding leveraged products long-term during volatile periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
